Holen Sie sich die Stockscreener-App
16.31
0.00%
0.00
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
RLYB|Rallybio Corp|Price:16.160|Chg%:-0.150 - TradingKey
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corporation Revenue Breakdown – FWB:33M0 - TradingView
Rallybio Corporation Revenue Breakdown – TRADEGATE:33M0 - TradingView
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics - Stock Titan
Total assets of Rallybio Corporation – FWB:33M0 - TradingView
Price to earnings forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Enterprise value to revenue forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Book value per share of Rallybio Corporation – FWB:33M0 - TradingView
Price to book forward of Rallybio Corporation – FWB:33M0 - TradingView
Long term debt to total equity ratio of Rallybio Corporation – FWB:33M0 - TradingView
Price to sales forward of Rallybio Corporation – FWB:33M0 - TradingView
Enterprise value to EBITDA forward of Rallybio Corporation – FWB:33M0 - TradingView
Net income before discontinued operations of Rallybio Corporation – FWB:33M0 - TradingView
Rallybio Corporation (RLYB) Edges Lower Amid Consolidation Near SupportLong Term Entry Picks - dars.gov.et
Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares - Stock Titan
Rallybio Corporation (RLYB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rallybio (RLYB) Drifts Marginally Lower, Consolidating Between Key Support and ResistanceTrade Entry Signals - DonanımHaber
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
Rallybio Company Profile & Introduction - Moomoo
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell 3000E Index - marketscreener.com
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
What's Driving Rallybio's Recent Surge and Investor Interest - Kavout | AI
Rallybio Corporation Actuals & Estimates (NASDAQ:RLYB) - TradingView
Rallybio Corporation (RLYB) Shows Modest Uptick, Testing Key Resistance LevelsLate Stage Breakouts - dars.gov.et
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RLYB Q1 2026 Earnings: Wider-Than-Expected Loss Underscores Pre-Revenue StageEarnings Call Q&A - dars.gov.et
Rallybio to Acquire Avenzo Therapeutics and Complete $215 Million Private Placement - Global Legal Chronicle
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):